Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. On average, analysts expect Contineum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Contineum Therapeutics Stock Down 4.2 %

NASDAQ CTNM traded down $0.43 during trading on Friday, hitting $9.79. 42,869 shares of the company's stock were exchanged, compared to its average volume of 74,525. Contineum Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $22.00. The stock's 50 day moving average price is $13.44 and its two-hundred day moving average price is $16.43.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CTNM. Baird R W upgraded shares of Contineum Therapeutics to a "strong-buy" rating in a research report on Tuesday, October 22nd. Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price target on shares of Contineum Therapeutics in a report on Thursday, January 9th. Finally, Robert W. Baird initiated coverage on Contineum Therapeutics in a report on Tuesday, October 22nd. They issued an "outperform" rating and a $32.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $29.25.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).